Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Eisai Submits Fycompa Pediatric Indications to FDA

Eisai Inc. submitted a supplemental New Drug Application for priority review to the U.S. FDA for the company’s antiepileptic drug Fycompa (perampanel) CIII as monotherapy and adjunctive use.

Read More »

New CDC Director Pledges to Take on AIDS and Opioid Epidemics

Days after being tapped to helm the U.S. Centers for Disease Control and Prevention (CDC), Dr. Robert Redfield predicted the AIDS epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”

Read More »

Researchers Develop Possible New RNA Therapy for West Nile Virus

A research group at Yale University and from Hanyang University, South Korea, developed a new RNA therapy for West Nile Virus.

Read More »

Sunovion Submits NDA for Sublingual PD Treatment

Sunovion Pharmaceuticals announced the submission of a new drug application to the U.S. FDA for apomorphine sublingual film to treat OFF episodes in Parkinson’s disease (PD).

Read More »

FDA Approves Amgen’s Blincyto for ALL

The FDA approved Amgen’s supplemental Biologic License Application for Blincyto (blinatumomab) to treat B-cell precursor acute lymphoblastic leukemia (ALL) under specific circumstances.

Read More »

Coffee sellers in California must have cancer warning

Starbucks Corp. and other coffee sellers must put a cancer warning on coffee sold in California, a Los Angeles judge ruled, possibly exposing the companies to millions of dollars in fines.

Read More »

Arkansas sues opioid manufacturers

Arkansas’ attorney general joined the widening mass of litigation against opioid manufacturers, accusing three drugmakers of promoting addictive painkillers in ways that falsely denied or trivialized their risks.

Read More »

Sandbox Opens Contemporary New Workspace in Kansas City

Sandbox announced the opening of the independent, full-service agency’s new office space in Kansas City, Mo., uniting its two local locations under one roof.

Read More »

Rare heart disease drug succeeds in late-stage study

Pfizer Inc.’s experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.

Read More »

Unum Captures Nearly $70 Million in IPO

In an initial public offering, Unum Therapeutics snagged nearly $70 million to fund its antibody-coupled T-cell receptor technology.

Read More »

MediciNova’s Drug Flunks Phase II Trial

La Jolla, Calif.-based MediciNova announced that the company’s Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.

Read More »

Edge Therapeutics Reports Phase III Failure of Brain-Bleed Drug, Prepares to Cut Staff

Shares of Edge Therapeutics were in a free fall following the company’s decision to discontinue development of a late-stage treatment for adults with aneurysmal subarachnoid hemorrhage.

Read More »

Lawsuits Allege Safety Concern Over Novartis CML Drug Tasigna

A Novartis leukemia drug continues to be the subject of a handful of lawsuits filed by plaintiffs due to concerns over atherosclerosis-related conditions.

Read More »

FDA Orphan Drug Designation Granted for MaxiNovel Pharmaceuticals’ MAX-40279 for the Treatment of Acute Myeloid Leukemia

  MaxiNovel Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for MAX-40279 for the Treatment of Acute Myeloid Leukemia (AML)   GUANGZHOU, China–(BUSINESS WIRE)–MaxiNovel Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has granted MaxiNovel Orphan Drug Designation for MAX-40279 in the treatment of Acute Myeloid Leukemia (AML). AML is the most […]

Read More »

Impax reaches $20 million deal to end trial over generic drug’s delay

Impax Laboratories Inc. agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of the acne medication Solodyn.

Read More »

Dr. Reddy’s Laboratories Announces Senior Leadership Changes

Dr. Reddy’s Laboratories Ltd. announced a change in the makeup of the company’s senior leadership team.

Read More »

Teva wins reversal of U.S. jury’s $235 million GSK drug patent verdict

A federal judge overturned a U.S. jury’s verdict that required Teva Pharmaceutical Industries Ltd. to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.

Read More »

FDA Approves Mylan’s New HIV Drug

The U.S. Food and Drug Administration approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients who weigh at least 40 kilograms.

Read More »

Celgene and bluebird bio Team Up in New Deal

Celgene Corp. and bluebird bio Inc. inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen CAR-T therapy for relapsed/refractory multiple myeloma.

Read More »

Homology Medicines Snags $144 Million IPO

Two months after securing a new facility in Bedford, Mass., Homology Medicines raised $144 million in an initial public offering of stock.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom